Johannes Fredebohm
Overview
Explore the profile of Johannes Fredebohm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
332
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kataoka K, Yamada T, Shiozawa M, Takase N, Ito K, Yamazaki K, et al.
J Anus Rectum Colon
. 2024 May;
8(2):132-136.
PMID: 38689780
Background: Spatial and temporal heterogeneities of RAS and other molecular genes should be considered in the treatment of metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor (EGFR) monoclonal...
2.
Diaz I, Nocon A, Held S, Kobilay M, Skowasch D, Bronkhorst A, et al.
Diagnostics (Basel)
. 2023 Apr;
13(7).
PMID: 37046506
Excellent pre-analytical stability is an essential precondition for reliable molecular profiling of circulating tumor DNA (ctDNA) in oncological diagnostics. Therefore, in vitro degradation of ctDNA and the additional release of...
3.
Economopoulou P, Spathis A, Kotsantis I, Maratou E, Anastasiou M, Moutafi M, et al.
Oral Oncol
. 2023 Mar;
139:106358.
PMID: 36871349
Objectives: The aim of this pilot study was to evaluate the presence of somatic mutations in matched tumor and circulating DNA (ctDNA) samples from patients with primary head and neck...
4.
Ciriaco N, Zamora E, Escriva-de-Romani S, Miranda Gomez I, Jimenez Flores J, Saura C, et al.
Ther Adv Med Oncol
. 2022 Dec;
14:17588359221139601.
PMID: 36479470
Background: Although the standard of care is to perform surgery of primary breast cancer (BC) after neoadjuvant chemotherapy (NAC), for certain patients achieving clinical complete response (cCR) and pathologic complete...
5.
Jeffers M, Kappeler C, Kuss I, Beckmann G, Mehnert D, Fredebohm J, et al.
Gastric Cancer
. 2022 Jan;
25(3):598-608.
PMID: 35050442
Background: In the phase 3 GRID trial, regorafenib improved progression-free survival (PFS) independent of KIT mutations in exons 9 and 11. In this retrospective, exploratory analysis of the GRID trial,...
6.
Rosenberg A, Izumchenko E, Pearson A, Gooi Z, Blair E, Karrison T, et al.
BMC Cancer
. 2022 Jan;
22(1):17.
PMID: 34980038
Background: Human papillomavirus (HPV)-associated oropharyngeal cancer (OPC) has a favorable prognosis which has led to efforts to de-intensify treatment. Response-adaptive de-escalated treatment is promising, however improved biomarkers are needed. Quantitative...
7.
Rodriguez B, Cordoba G, Aranda A, Alvarez M, Vicioso L, Perez C, et al.
J Clin Med
. 2019 Aug;
8(8).
PMID: 31394872
Circulating tumor DNA (ctDNA) has emerged as a non-invasive "liquid biopsy" for early breast cancer diagnosis. We evaluated the suitability of ctDNA analysis in the diagnosis of early breast cancer...
8.
Kaistha B, Krattenmacher A, Fredebohm J, Schmidt H, Behrens D, Widder M, et al.
Oncotarget
. 2017 Oct;
8(39):66215-66225.
PMID: 29029505
Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal solid tumors. With an overall five-year survival rate remaining below 6%, there is an explicit need to search for new...
9.
Diaz I, Nocon A, Mehnert D, Fredebohm J, Diehl F, Holtrup F
PLoS One
. 2016 Nov;
11(11):e0166354.
PMID: 27832189
Objectives: Making liquid biopsy testing widely available requires a concept to ship whole blood at ambient temperatures while retaining the integrity of the cell-free DNA (cfDNA) population and stability of...
10.
Fredebohm J, Mehnert D, Lober A, Holtrup F, van Rahden V, Angenendt P, et al.
Adv Exp Med Biol
. 2016 Oct;
924:187-189.
PMID: 27753042
We have designed a highly sensitive assay based on the Safe-SeqS technology to detect de novo mutations in the KIT gene and tested its performance. This assay was applied to...